Hematology, Oncology and Drug Updates: 2024
-
Register
- Non-member - Free!
- Member - Free!
Already registered?
Log in now.
Tune in to stay updated with the latest advancements in hematology, oncology from the ASCO 2024 conference, and FDA drug approvals.
- Hematology Update from ASCO 2024: Discusses key findings in hematology, including new research and treatment approaches.
- Solid Tumor Oncology Update from ASCO 2024: Covers the latest in solid tumor treatments and their clinical implications.
- Drug Approval Updates: Reviews the newest drug approvals and their potential impact on patient care
By watching this webinar, advanced practitioners will gain critical insights into the latest research, innovative treatments, and new drug approvals, enhancing their ability to provide cutting-edge care to patients.
Katie Sellers (Moderator)
MPAS, PA-C
Texas Oncology, Dallas, TX
No relevant financialrelationships to disclose
Andrew Guinigundo (Moderator)
MSN, RN, CNP, ANP-BC, FAPO
Cincinnati Cancer Advisors, OH
Speakers’ Bureau: Amgen, Astellas, AstraZeneca, GSK, Natera,Pfizer
Consulting:Amgen, AstraZeneca
Megan May (Moderator)
PharmD, BCOP, FHOPA, FAPO
Baptist Health Lexington, KY
Advisory Board: Lilly, Genentech, Pfizer, AstraZeneca, Daiichi Sankyo, GlaxoSmithKline
Speakers’Bureau: Amgen, AstraZeneca
Consulting:Amgen, Lilly
Key:
Complete
Next
Failed
Available
Locked
Hematology, Oncology and Drug Updates: 2024
Open to view video. | 90 minutes
Open to view video. | 90 minutes
Outline:
- Faculty Introduction and disclosures
- Hematology Update from ASCO 2024: Katie Sellers
- Solid Tumor Oncology Update from ASCO 2024: Andrew Guinigundo
- Drug Approval Updates: Megan May
